Stay updated with breaking news from Resure sealant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ocular Therapeutix (NASDAQ: OCUL) has recently received a number of price target changes and ratings updates: 3/10/2024 – Ocular Therapeutix was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating. 3/2/2024 – Ocular Therapeutix was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/26/2024 – Ocular […] ....
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) is set to release its earnings data after the market closes on Monday, March 11th. Analysts expect Ocular Therapeutix to post earnings of ($0.28) per share for the quarter. Ocular Therapeutix Stock Down 3.8 % Shares of NASDAQ OCUL opened at $9.98 on Friday. The company’s 50-day simple […] ....
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) major shareholder Summer Road Llc purchased 930,851 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 26th. The stock was acquired at an average price of $7.52 per share, with a total value of $6,999,999.52. Following the transaction, the insider now owns 8,591,401 […] ....
Ocular Therapeutix (NASDAQ:OCUL – Free Report) had its price target raised by Piper Sandler from $10.00 to $15.00 in a report issued on Monday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently commented on the stock. Bank of America started […] ....
Paradigm Capital Management Inc. NY increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 100.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,000 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 shares […] ....